Valuation dashboard for Acadia Pharmaceuticals Inc. (ACAD) with P/E 9.22, P/B 2.69, EV/EBITDA 27.9 and dividend yield 0.00%. DCF, Graham Number, EPS growth, peer multiples and dividend discount models plus sector comparison against other Healthcare companies.
Acadia Pharmaceuticals Inc. operates as a biopharmaceutical company, primarily dedicated to discovering, developing, and commercializing small molecule therapeutics. Their core focus lies in addressing critical unmet medical needs within the realm of central nervous system (CNS) disorders. The company's marketed product, NUPLAZID (pimavanserin), is prescribed for the management of hallucinations and delusions associated with Parkinson's disease psychosis.
Analysis Summary
Acadia Pharmaceuticals Inc. reported revenue of $1.07B in the most recent fiscal year, growing at a 5-year CAGR of 19.4%.
Trailing-twelve-month margins: gross margin 91.1%, operating margin 7.6%, net margin 33.4%.
At $20.47 (closing price, November 2, 2026), ACAD trades at a P/E of 9.22 and an ROE of 32.39%. Market capitalisation stands at $3.5B.
Balance sheet quality for ACAD: debt-to-equity ratio of 0.06, current ratio of 3.39 over the last 12 months. A debt-to-equity below 1.0 typically signals conservative capital structure, while a current ratio above 1.5 indicates comfortable short-term liquidity.
Valuation Ratios
| P/E Ratio | 9.22 |
| Price / Book | 2.69 |
| EV / EBITDA | 27.9 |
| Dividend Yield | 0.00% |
Peer Comparison
| Symbol | Company | Market Cap | P/E | P/B | ROE |
|---|---|---|---|---|---|
| ACAD | Acadia Pharmaceuticals Inc. | $3.5B | 9.22 | 2.69 | 32.4% |
| AXSM | Axsome Therapeutics, Inc. | $7.1B | 67.65 | -189.7% | |
| PRAX | Praxis Precision Medicines, Inc. | $7.6B | 5.95 | -34.1% | |
| VRTX | Vertex Pharmaceuticals Incorporated | $140.2B | 35.60 | 4.28 | 17.5% |
| 0QZU.L | Vertex Pharmaceuticals Incorporated | $134.0B | 30.25 | 6.57 | 23.3% |
| REGN | Regeneron Pharmaceuticals, Inc. | $99.0B | 21.24 | 2.92 | 15.1% |
| MRNA | Moderna, Inc. | $88.2B | 12.93 | -39.2% | |
| 0R2M.L | Regeneron Pharmaceuticals, Inc. | $86.5B | 19.22 | 2.62 | 13.8% |
Price
| Price | $20.47 (closing price, November 2, 2026) |
| Market Cap | $3.5B |
| Exchange | NASDAQ |
| Country | US |
Profitability
| Return on Equity | 32.39% |
| Return on Invested Capital | 6.19% |
| Return on Assets | 21.83% |
| Gross Margin | 91.13% |
| Operating Margin | 7.59% |
| Net Margin | 33.42% |
Related companies: AXSM · PRAX · VRTX · 0QZU.L · REGN · MRNA · 0R2M.L · ARGX
Explore sector: Healthcare · Biotechnology
More sections of ACAD: Overview · Financials · Statistics · Estimates · Technical · Ownership · News · Events
Discover more: Weekly Radar: the S&P 500 through the Buffett and Lynch methods · Companies that pass the Buffett method · Companies that pass the Lynch method · Stocks that pass Graham's defensive investor test today · Investment Academy — learn to analyze stocks